Question 1
A 42-year-old patient experiences breakthrough bipolar depression while taking a therapeutic dose of lithium. The patient's recent physical exam reveals elevated fasting blood glucose and significant weight gain. Which adjunctive medication recommendation is most appropriate?
▸ Why C is the answer
Lurasidone is an FDA-approved adjunct for bipolar depression that has a highly favorable metabolic profile, making it safe despite the patient's elevated blood glucose. Olanzapine and quetiapine are also effective for bipolar depression but carry significant risks for exacerbating weight gain and metabolic syndrome. Venlafaxine is an antidepressant that risks inducing a manic switch even with lithium on board. Key Takeaway: Lurasidone effectively treats breakthrough bipolar depression while offering a favorable metabolic profile for patients with elevated glucose.